Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: EMBC

Embecta Corp.

Healthcare | Drug Manufacturers - Specialty & Generic

No licensed closing price on file for EMBC. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$1.47

Embecta Corp. (NASDAQ: EMBC) is a specialty and generic drug manufacturer. Figures from SEC EDGAR; updated 2026-10-20 16:48 UTC.

What Embecta Corp. does

Embecta is a global medical device company focused on diabetes management solutions, including pen needles, syringes, and safety injection devices used by millions of people across many countries. The company operates manufacturing sites in multiple locations and distributes products through various channels worldwide, including retail, hospitals, and pharmacies. Embecta competes in the diabetes care industry based on factors such as product quality, clinical innovation, price, and service.

Summarized from Embecta Corp.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$1.47
Return on equity-14.66%

Revenue, margins & earnings

FY2021 Net income: $415MFY2021 Taxes & interest: $77MFY2021 Operating expenses: $308MFY2021 Cost of revenue: $365M$1.17BFY2021FY2022 Net income: $224MFY2022 Taxes & interest: $86MFY2022 Operating expenses: $465MFY2022 Cost of revenue: $355M$1.13BFY2022FY2023 Net income: $70MFY2023 Taxes & interest: $151MFY2023 Operating expenses: $528MFY2023 Cost of revenue: $371M$1.12BFY2023FY2024 Net income: $78MFY2024 Taxes & interest: $88MFY2024 Operating expenses: $568MFY2024 Cost of revenue: $388M$1.12BFY2024FY2025 Net income: $95MFY2025 Taxes & interest: $147MFY2025 Operating expenses: $435MFY2025 Cost of revenue: $404M$1.08BFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-08
  • 2026-09-08DirectorSale-6,293$37.0K
  • 2026-08-13Pres, Pharm Svc&Prod Mgmt, CLOPurchase20,000$99.8K
  • 2026-08-13President and CEOPurchase30,000$140.9K
Sign in to see all transactions →

Company news

View all →

Questions this page answers

What does Embecta Corp. do?

Embecta is a global medical device company focused on diabetes management solutions, including pen needles, syringes, and safety injection devices used by millions of people across many countries.

When did EMBC last file with the SEC?

Embecta Corp.'s most recent SEC filing on record is a SCHEDULE 13G/A filed 2026-08-14. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 16:48 UTC. This page is also available as JSON at /api/data?ticker=EMBC and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for EMBC and 5,000+ tickers.

Create a free account — keep EMBC
For your agent
GET /api/data?ticker=EMBC

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt